Spectrum: Local Antimicrobial Stewardship, for Saskatchewan Health Authority - Saskatoon Area

Daptomycin

Restricted
Restricted

C. diff Risk

Low

Oral Bioavailability

NA

Spectrum Of Activity

General Spectrum of Activity

Spectrum Of Activity

Dosing

Renal

Hepatic

Unknown for severe hepatic dysfunction

Adult

MRSA bacteremia OR Endocarditis
6-10 mg/kg IV daily

Usual dose
4-6 mg/kg IV daily

Must be approved by Infectious Diseases

Restricted Use

This antimicrobial is restricted to Infectious Diseases

General Information

Common Usage

Common Usage

Targeted therapy of resistant gram positive infections with MRSA (particularly when MIC≥2) and VRE including endovascular infection

Drug Monitoring

Drug Monitoring

Creatine kinase weekly

Adverse Effects

Adverse Effects

  • GI side effects common

  • Rash

  • Phlebitis

  • Increased INR

  • Myopathy including rhabdomyolysis

Major Interactions

Major Interactions

Statins and fibrates - Increased myopathy. Monitor creatine kinase or hold while on daptomycin therapy.

Additional Information

Additional Information

Higher doses used for endovascular infection.

Recommend Infectious Disease Consult.

Inactivated by pulmonary surfactant and therefore insufficient for pulmonary infection.

Pharmacology

Pharmacology

Antimicrobial class: Cyclic Lipopeptide.

Pregnancy category: B

Average serum half life: 9 hours

CSF penetration: Poor

Lung penetration: Poor

Urine penetration: Therapeutic